Thang V. Pham

Thang V. Pham

Auto-generated profile, based on publicly available information

Thang V. Pham

Amsterdam UMC location Vrije Universiteit Amsterdam, OncoProteomics Laboratory, Department of Medical Oncology, van der Boechorststraat 6B, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2009 in Bioinformatics
Verified
Journal Article
Open access
PDF file
TPThang V. Pham
Thang V. Pham
SPSander R. Piersma
Sander R. Piersma
MWMarc Warmoes
Marc Warmoes
CJConnie R. Jimenez
Connie R. Jimenez
Motivation: Spectral count data generated from label-free tandem mass spectrometry-based proteomic experiments can be used to quantify protein's abundances reliably. Comparing spectral count data from different sample groups such as control and disease is an essential step in statistical analysis for the determination of altered protein level and biomarker discovery. The Fisher's exact test, the G-test, the t-test and the local-pooled-error technique (LPE) are commonly used for differential analysis of spectral count data. However, our initial experiments in two cancer studies show that the current methods are unable to declare at 95% confidence level a number of protein markers that have been judged to be differential on the basis of the biology of the disease and the spectral count numbers. A shortcoming of these tests is that they do not take into account within- and between-sample variations together. Hence, our aim is to improve upon existing techniques by incorporating both the within- and between-sample variations. Result: We propose to use the beta-binomial distribution to test the significance of differential protein abundances expressed in spectral counts in label-free mass spectrometry-based proteomics. The beta-binomial test naturally normalizes for total sample count. Experimental results show that the beta-binomial test performs favorably in comparison with other methods on several datasets in terms of both true detection rate and false positive rate. In addition, it can be applied for experiments with one or more replicates, and for multiple condition comparisons. Finally, we have implemented a software package for parameter estimation of two beta-binomial models and the associated statistical tests. Availability and implementation: A software package implemented in R is freely available for download at http://www.oncoproteomics.nl/. Contact:t.pham@vumc.nl Supplementary information: Supplementary data are available at Bioinformatics online.

7 January 2020 in Bioinformatics
Verified
Journal Article
Open access
PDF file
TPThang V Pham
Thang V Pham
AHAlex A Henneman
Alex A Henneman
CJConnie R Jimenez
Connie R Jimenez
We present an R package called iq to enable accurate protein quantification for label-free data-independent acquisition (DIA) mass spectrometry-based proteomics, a recently developed global approach with superior quantitative consistency. We implement the popular maximal peptide ratio extraction module of the MaxLFQ algorithm, so far only applicable to data-dependent acquisition mode using the software suite MaxQuant. Moreover, our implementation shows, for each protein separately, the validity of quantification over all samples. Hence, iq exports a state-of-the-art protein quantification algorithm to the emerging DIA mode in an open-source implementation. The open-source R package is available on CRAN, https://github.com/tvpham/iq/releases and oncoproteomics.nl/iq. Supplementary data are available at Bioinformatics online.

1 January 2021 in Circulation: Heart Failure
Verified
Journal Article
Open access
PDF file
MSMaike Schuldt
Maike Schuldt
JPJiayi Pei
Jiayi Pei
MHMagdalena Harakalova
Magdalena Harakalova
LDLarissa Dorsch
Larissa Dorsch
SSSaskia Schlossarek
Saskia Schlossarek
DKDiederik W.D. Kuster
Diederik W.D. Kuster
Background: Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease. While ≈50% of patients with HCM carry a sarcomere gene mutation (sarcomere mutation-positive, HCM SMP ), the genetic background is unknown in the other half of the patients (sarcomere mutation-negative, HCM SMN ). Genotype-specific differences have been reported in cardiac function. Moreover, HCM SMN patients have later disease onset and a better prognosis than HCM SMP patients. To define if genotype-specific derailments at the protein level may explain the heterogeneity in disease development, we performed a proteomic analysis in cardiac tissue from a clinically well-phenotyped HCM patient group. Methods: A proteomics screen was performed in cardiac tissue from 39 HCM SMP patients, 11HCM SMN patients, and 8 nonfailing controls. Patients with HCM had obstructive cardiomyopathy with left ventricular outflow tract obstruction and diastolic dysfunction. A novel MYBPC3 2373insG mouse model was used to confirm functional relevance of our proteomic findings. Results: In all HCM patient samples, we found lower levels of metabolic pathway proteins and higher levels of extracellular matrix proteins. Levels of total and detyrosinated α-tubulin were markedly higher in HCM SMP than in HCM SMN and controls. Higher tubulin detyrosination was also found in 2 unrelated MYBPC3 mouse models and its inhibition with parthenolide normalized contraction and relaxation time of isolated cardiomyocytes. Conclusions: Our findings indicate that microtubules and especially its detyrosination contribute to the pathomechanism of patients with HCM SMP . This is of clinical importance since it represents a potential treatment target to improve cardiac function in patients with HCM SMP , whereas a beneficial effect may be limited in patients with HCM SMN .

1 April 2020 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
TZTiansheng Zhu
Tiansheng Zhu
YZYi Zhu
Yi Zhu
YXYue Xuan
Yue Xuan
HGHuanhuan Gao
Huanhuan Gao
XCXue Cai
Xue Cai
TGTiannan Guo
Tiannan Guo
To address the increasing need for detecting and validating protein biomarkers in clinical specimens, mass spectrometry (MS)-based targeted proteomic techniques, including the selected reaction monitoring (SRM), parallel reaction monitoring (PRM), and massively parallel data-independent acquisition (DIA), have been developed. For optimal performance, they require the fragment ion spectra of targeted peptides as prior knowledge. In this report, we describe a MS pipeline and spectral resource to support targeted proteomics studies for human tissue samples. To build the spectral resource, we integrated common open-source MS computational tools to assemble a freely accessible computational workflow based on Docker. We then applied the workflow to generate DPHL, a comprehensive DIA pan-human library, from 1096 data-dependent acquisition (DDA) MS raw files for 16 types of cancer samples. This extensive spectral resource was then applied to a proteomic study of 17 prostate cancer (PCa) patients. Thereafter, PRM validation was applied to a larger study of 57 PCa patients and the differential expression of three proteins in prostate tumor was validated. As a second application, the DPHL spectral resource was applied to a study consisting of plasma samples from 19 diffuse large B cell lymphoma (DLBCL) patients and 18 healthy control subjects. Differentially expressed proteins between DLBCL patients and healthy control subjects were detected by DIA-MS and confirmed by PRM. These data demonstrate that the DPHL supports DIA and PRM MS pipelines for robust protein biomarker discovery. DPHL is freely accessible at https://www.iprox.org/page/project.html?id=IPX0001400000.

3 September 2012 in Bioinformatics
Verified
Journal Article
Open access
PDF file
TPThang V. Pham
Thang V. Pham
CJConnie R. Jimenez
Connie R. Jimenez
Motivation: Recent technology platforms in proteomics and genomics produce count data for quantitative analysis. Previous works on statistical significance analysis for count data have mainly focused on the independent sample setting, which does not cover the case where pairs of measurements are taken from individual patients before and after treatment. This experimental setting requires paired sample testing such as the paired t-test often used for continuous measurements. A state-of-the-art method uses a negative binomial distribution in a generalized linear model framework for paired sample testing. A paired sample design assumes that the relative change within each pair is constant across biological samples. This model can be used as an approximation to the true model in cases of heterogeneity of response in complex biological systems. We aim to specify the variation in response explicitly in combination with the inherent technical variation. Results: We formulate the problem of paired sample test for count data in a framework of statistical combination of multiple contingency tables. In particular, we specify explicitly a random distribution for the effect with an inverted beta model. The technical variation can be modeled by either a standard Poisson distribution or an exponentiated Poisson distribution, depending on the reproducibility of the acquisition workflow. The new statistical test is evaluated on both proteomics and genomics datasets, showing a comparable performance to the state-of-the-art method in general, and in several cases where the two methods differ, the proposed test returns more reasonable p-values. Availability: Available for download at http://www.oncoproteomics.nl/. Contact: t.pham@vumc.nl

1 December 2017 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
IBIrene Bijnsdorp
Irene Bijnsdorp
OMOlga Maxouri
Olga Maxouri
AKAarzo Kardar
Aarzo Kardar
TSTim Schelfhorst
Tim Schelfhorst
SPSander R. Piersma
Sander R. Piersma
CJConnie R Jimenez
Connie R Jimenez
Extracellular vesicles (EVs) secreted by prostate cancer (PCa) cells contain specific biomarkers and can be isolated from urine. Collection of urine is not invasive, and therefore urinary EVs represent a liquid biopsy for diagnostic and prognostic testing for PCa. In this study, we optimised urinary EV isolation using a method based on heat shock proteins and compared it to gold‐standard ultracentrifugation. The urinary EV isolation protocol using the Vn96‐peptide is easier, time convenient (≈1.5 h) and no special equipment is needed, in contrast to ultracentrifugation protocol (>3.5 h), making this protocol clinically feasible. We compared the isolated vesicles of both ultracentrifugation and Vn96‐peptide by proteome profiling using mass spectrometry‐based proteomics (n = 4 per method). We reached a depth of >3000 proteins, with 2400 proteins that were commonly detected in urinary EVs from different donors. We show a large overlap (>85%) between proteins identified in EVs isolated by ultracentrifugation and Vn96‐peptide. Addition of the detergent NP40 to Vn96‐peptide EV isolations reduced levels of background proteins and highly increased the levels of the EV‐markers TSG101 and PDCD6IP, indicative of an increased EV yield. Thus, the Vn96‐peptide‐based EV isolation procedure is clinically feasibly and allows large‐scale protein profiling of urinary EV biomarkers.